JP2022071072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022071072A5 JP2022071072A5 JP2022030942A JP2022030942A JP2022071072A5 JP 2022071072 A5 JP2022071072 A5 JP 2022071072A5 JP 2022030942 A JP2022030942 A JP 2022030942A JP 2022030942 A JP2022030942 A JP 2022030942A JP 2022071072 A5 JP2022071072 A5 JP 2022071072A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- compound
- crystals
- pharmaceutical composition
- amorphous form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 57
- 229940125904 compound 1 Drugs 0.000 claims 19
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 8
- 239000003960 organic solvent Substances 0.000 claims 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 4
- 235000019439 ethyl acetate Nutrition 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000009477 glass transition Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Claims (33)
- 化合物１の結晶であって、
前記結晶は、無水物であり、
Ｘ線粉末回折パターンが１４．８±０．２°、１５．６±０．２°、１６．４±０．２°及び２１．４±０．２°から独立して選択される２θ角度値を有する回折ピークを含む、結晶。 - Ｘ線粉末回折パターンが１２．２±０．２°、１２．９±０．２°、１４．８±０．２°、１５．６±０．２°、１６．４±０．２°及び２１．４±０．２°から独立して選択される２θ角度値を有する回折ピークを含むことを特徴とする、請求項１に記載の結晶。
- Ｘ線粉末回折パターンが１２．２±０．２°、１２．９±０．２°、１４．８±０．２°、１５．６±０．２°、１６．４±０．２°、１７．７±０．２°、１８．５±０．２°、２０．７±０．２°及び２１．４±０．２°から独立して選択される２θ角度値を有する回折ピークを含むことを特徴とする、請求項１に記載の結晶。
- 結晶の融点が１３９±２℃（開始温度）であることを特徴とする、請求項１～３のいずれかに記載の結晶。
- 請求項１～４のいずれかに記載の結晶を調製する方法であって、以下のいずれかのステップを含む：
（ａ）化合物１をＤＣＭに溶解し、溶媒ＥＡに交換し、ＥＡ／ＭＴＢＥから再結晶するステップを経て目的の結晶を得る；
（ｂ）化合物１をＥＡに溶解し、ヘキサンを添加するステップを経て目的の結晶を得る；
（ｃ）化合物１を有機溶媒に溶解し、Ｈ２Ｏを添加するステップを経て目的の結晶を得るところ、前記有機溶媒がアセトン又はＤＭＡｃである；
（ｄ）請求項１～４のいずれかに記載の結晶を有機溶媒に溶解し、Ｈ２Ｏを加えるステップを経て目的の結晶を得るところ、前記有機溶媒がアセトン又はＤＭＡｃである；
（ｅ）化合物１を有機溶媒に溶解し、ｎ－ヘプタンを加えるステップを経て目的の結晶を得るところ、前記有機溶媒がＥｔＯＡｃ、ＤＣＭ、トルエン又は２－ＭｅＴＨＦである；
（ｆ）請求項１～４のいずれかに記載の結晶を有機溶媒に溶解し、ｎ－ヘプタンを添加するステップを経て、目的の結晶を得るところ、前記有機溶媒がＥｔＯＡｃ、ＤＣＭ、トルエン又は２－ＭｅＴＨＦである；
（ｇ）化合物１をアセトン又はＥｔＯＡｃに溶解して溶液を得て、前記溶液をｎ－ヘプタンに入れ、室温で蒸発させるステップを経て、目的の結晶を得る；
（ｈ）請求項１～４のいずれか１項に記載の結晶をアセトン又はＥｔＯＡｃに溶解して溶液を得て、この溶液をｎ－ヘプタンに入れ、室温で蒸発させるステップを経て、目的の結晶を得る、方法。 - 請求項１～４のいずれかに記載の結晶が９０％を超えるｅｅ値を有する、請求項５に記載の方法。
- 請求項１～４のいずれかに記載の結晶及び薬学上許容される賦形剤を含む、医薬組成物。
- 経口投与に適合する、請求項７に記載の医薬組成物。
- １重量％～９９重量％の請求項１～４のいずれかに記載の結晶を含む、請求項７又は８に記載の医薬組成物。
- １重量％～７０重量％の請求項１～４のいずれかに記載の結晶を含む、請求項７又は８に記載の医薬組成物。
- １０重量％～３０重量％の請求項１～４のいずれかに記載の結晶を含む、請求項７又は８に記載の医薬組成物。
- 対象におけるＢｔｋ活性の異常に関連する疾患を治療するための、請求項７～１１のいずれかに記載の医薬組成物。
- 前記疾患が、アレルギー性疾患、自己免疫疾患、炎症性疾患、癌、若しくはＢ細胞悪性腫瘍から選択されるＢ細胞増殖性疾患又はそれらの２つ以上の組み合わせから選択される疾患である、請求項１２に記載の医薬組成物。
- 前記Ｂ細胞増殖性疾患が、リンパ腫、非ホジキンリンパ腫（ＮＨＬ）、びまん性大細胞型Ｂ細胞リンパ腫（ＤＬＢＣＬ）、マントル細胞リンパ腫（ＭＣＬ）、濾胞性リンパ腫（ＦＬ）、慢性リンパ性白血病（ＣＬＬ）、小リンパ性リンパ腫（ＳＬＬ）、ワルデンストロームマクログロブリン血症（ＷＭ）、辺縁帯リンパ腫（ＭＺＬ）、有毛細胞白血病（ＨＣＬ）、バーキット様白血病（ＢＬ）、及びそれらの２つ以上の組み合わせから選択されるＢ細胞悪性腫瘍である請求項１３に記載の医薬組成物。
- 前記Ｂ細胞増殖性疾患が、再発／難治性マントル細胞リンパ腫（Ｒ／Ｒ ＭＣＬ）、再発／難治性慢性リンパ性白血病（Ｒ／Ｒ ＣＬＬ）、再発／難治性の小リンパ球性リンパ腫（Ｒ／Ｒ ＳＬＬ）、再発／難治性ワルデンストレームマクログロブリン血症（Ｒ／Ｒ ＷＭ）及びそれらの２つ以上の組み合わせから選択される再発／難治性Ｂ細胞悪性腫瘍である、請求項１３に記載の医薬組成物。
- 請求項１～４のいずれかに記載の結晶を４０ｍｇ～３２０ｍｇの用量で投与するのに適合する、請求項７～１１のいずれかに記載の医薬組成物。
- 請求項１～４のいずれかに記載の結晶を１日２回（ＢＩＤ）１６０ｍｇ又は１日１回（ＱＤ）３２０ｍｇの用量で投与する、請求項７～１１のいずれかに記載の医薬組成物。
- 非晶形の化合物１であって、
約７９．７℃のガラス転移温度の中点温度を有する、非晶形の化合物１。 - 少なくとも９０％のｅｅ値を有する、請求項１８に記載の非晶形の化合物１。
- 少なくとも９７％のｅｅ値を有する、請求項１９に記載の非晶形の化合物１。
- 非晶形の化合物１から化合物１の結晶を再結晶することで得られた、化合物１の結晶。
- 前記非晶形の化合物１が少なくとも９０％のｅｅ値を有する、請求項２１に記載の結晶。
- 前記結晶が少なくとも４５％のｅｅ値を有する、請求項２２に記載の結晶。
- 前記非晶形の化合物１が少なくとも９７％のｅｅ値を有する、請求項２１に記載の結晶。
- 前記結晶が少なくとも９９．３％の純度を有する、請求項２２に記載の結晶。
- 前記結晶が少なくとも９９．５％の純度を有する、請求項２５に記載の結晶。
- 前記非晶形の化合物１が約７９．７℃のガラス転移温度の中点温度を有し、
前記非晶形の化合物１が少なくとも９７％のｅｅ値を有し、
前記結晶が１３９±２℃の融点（開始温度）を有し、
前記結晶が約８０℃で２日間、貯蔵した後に結晶形が変化しない、
前記結晶が約２５℃で６０％相対湿度で２４ヶ月間、貯蔵した後に結晶形が変化しない、
前記結晶が約４０℃で７５％相対湿度で６ヶ月間、貯蔵した後に結晶形が変化しない、請求項２６に記載の結晶。 - 前記非晶形の化合物１が約７９．７℃のガラス転移温度の中点温度を有する、請求項２１に記載の結晶。
- 前記結晶が１３９±２℃の融点（開始温度）を有する、請求項２１に記載の結晶。
- 前記結晶が約８０℃で２日間、貯蔵した後に結晶形が変化しない、請求項２１に記載の結晶。
- 前記結晶が約２５℃で６０％相対湿度で２４ヶ月間、貯蔵した後に結晶形が変化しない、請求項２１に記載の結晶。
- 前記結晶が約４０℃で７５％相対湿度で６ヶ月間、貯蔵した後に結晶形が変化しない、請求項２１に記載の結晶。
- 前記結晶のＸ線粉末回折パターンが１４．８±０．２°、１６．４±０．２°及び２１．４±０．２°の２θ角度値を有する回折ピークを含む、請求項２１に記載の結晶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023220256A JP2024026550A (ja) | 2016-08-16 | 2023-12-27 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016095510 | 2016-08-16 | ||
| CNPCT/CN2016/095510 | 2016-08-16 | ||
| PCT/IB2017/054955 WO2018033853A2 (en) | 2016-08-16 | 2017-08-15 | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| JP2019508889A JP7402685B2 (ja) | 2016-08-16 | 2017-08-15 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508889A Division JP7402685B2 (ja) | 2016-08-16 | 2017-08-15 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220256A Division JP2024026550A (ja) | 2016-08-16 | 2023-12-27 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022071072A JP2022071072A (ja) | 2022-05-13 |
| JP2022071072A5 true JP2022071072A5 (ja) | 2022-12-13 |
| JP7413419B2 JP7413419B2 (ja) | 2024-01-15 |
Family
ID=61197220
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508889A Active JP7402685B2 (ja) | 2016-08-16 | 2017-08-15 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
| JP2022030942A Active JP7413419B2 (ja) | 2016-08-16 | 2022-03-01 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
| JP2023220256A Pending JP2024026550A (ja) | 2016-08-16 | 2023-12-27 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508889A Active JP7402685B2 (ja) | 2016-08-16 | 2017-08-15 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023220256A Pending JP2024026550A (ja) | 2016-08-16 | 2023-12-27 | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US10927117B2 (ja) |
| EP (2) | EP3500575A4 (ja) |
| JP (3) | JP7402685B2 (ja) |
| KR (2) | KR20230162137A (ja) |
| CN (3) | CN109563099B (ja) |
| AU (3) | AU2017314178B2 (ja) |
| BR (1) | BR112019003205A8 (ja) |
| CA (1) | CA3033827A1 (ja) |
| EA (1) | EA201990519A1 (ja) |
| IL (2) | IL264784B (ja) |
| MX (1) | MX2019001900A (ja) |
| NZ (1) | NZ751418A (ja) |
| SG (1) | SG11201901141WA (ja) |
| TW (2) | TW202233628A (ja) |
| WO (1) | WO2018033853A2 (ja) |
| ZA (1) | ZA201900919B (ja) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE031980T2 (en) | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
| CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
| EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
| CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CN111675711A (zh) * | 2019-03-11 | 2020-09-18 | 百济神州(苏州)生物科技有限公司 | Btk抑制剂化合物的单晶及其制备方法 |
| CN117820311A (zh) * | 2019-05-08 | 2024-04-05 | 百济神州(苏州)生物科技有限公司 | Btk抑制剂及其中间体的制备方法 |
| KR20220016049A (ko) * | 2019-05-31 | 2022-02-08 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | Btk 억제제 고리 유도체, 이의 제조 방법 및 이의 약제학적 응용 |
| CN112057432A (zh) * | 2019-06-10 | 2020-12-11 | 百济神州(苏州)生物科技有限公司 | 口服胶囊剂及其制备方法 |
| US20220249491A1 (en) * | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| TW202112369A (zh) * | 2019-06-10 | 2021-04-01 | 英屬開曼群島商百濟神州有限公司 | 口服膠囊劑及其製備方法 |
| CN112057427A (zh) * | 2019-06-10 | 2020-12-11 | 百济神州(苏州)生物科技有限公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| CN110563733A (zh) * | 2019-09-12 | 2019-12-13 | 安帝康（无锡）生物科技有限公司 | 作为选择性btk抑制剂的咪唑并吡嗪类化合物 |
| KR20220110260A (ko) * | 2019-12-04 | 2022-08-05 | 허난 즈웨이 바이오메디슨 씨오., 엘티디. | 브루톤 티로신 키나제 억제제인 이미다졸 카복사마이드 유도체 |
| CN110922409A (zh) * | 2019-12-19 | 2020-03-27 | 武汉九州钰民医药科技有限公司 | 制备btk抑制剂泽布替尼的方法 |
| CN110845504A (zh) * | 2019-12-19 | 2020-02-28 | 武汉九州钰民医药科技有限公司 | 合成赞布替尼的新方法 |
| CN110938077B (zh) * | 2019-12-25 | 2021-04-27 | 武汉九州钰民医药科技有限公司 | 合成Avapritinib的方法 |
| US20230089557A1 (en) * | 2020-02-27 | 2023-03-23 | Beigene Switzerland Gmbh | Methods of treating dlbcl using btk inhibitors and combinations thereof |
| WO2021259732A1 (en) | 2020-06-24 | 2021-12-30 | Sandoz Ag | Multi-component compounds comprising zanubrutinib and a benzoic acid derivative |
| US20230248833A1 (en) | 2020-07-07 | 2023-08-10 | Sichuan Haisco Pharmaceutical Co., Ltd. | Compound having btk kinase degrading activity, and preparation method and pharmaceutical use therefor |
| WO2022101939A1 (en) * | 2020-11-13 | 2022-05-19 | Msn Laboratories Private Limited, R&D Center | Novel process for the preparation of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or its salts thereof |
| KR20230107866A (ko) * | 2020-11-20 | 2023-07-18 | 베이진 스위찰랜드 게엠베하 | Btk 억제제를 사용한 전신성 홍반성 루푸스의 치료 방법 |
| US20240124461A1 (en) | 2020-12-11 | 2024-04-18 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of zanubrutinib and intermediates thereof |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
| IT202100025997A1 (it) * | 2021-10-11 | 2023-04-11 | Olon Spa | Processo per la preparazione di zanubrutinib |
| IT202200009872A1 (it) * | 2022-05-12 | 2023-11-12 | Olon Spa | Processo di preparazione di Zanubrutinib in forma amorfa. |
| CN117430610A (zh) * | 2023-10-11 | 2024-01-23 | 宁夏医科大学 | 一种氘代稠合杂环化合物及其制备方法和应用 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792533A (fr) | 1971-12-09 | 1973-06-08 | Int Chem & Nuclear Corp | Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation |
| JP2778921B2 (ja) | 1994-11-18 | 1998-07-23 | 三共株式会社 | イミダゾピラゾール誘導体 |
| ES2222919T3 (es) | 1999-08-27 | 2005-02-16 | Abbott Laboratories | Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2. |
| EP1212327B8 (en) * | 1999-09-17 | 2004-02-25 | Abbott GmbH & Co. KG | Pyrazolopyrimidines as therapeutic agents |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20020094989A1 (en) * | 2000-10-11 | 2002-07-18 | Hale Jeffrey J. | Pyrrolidine modulators of CCR5 chemokine receptor activity |
| EP1347971B1 (en) | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
| WO2002072576A1 (en) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| WO2003004497A1 (fr) | 2001-07-05 | 2003-01-16 | Sumitomo Pharmaceuticals Company, Limited | Compose heterocyclique |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| ZA200500782B (en) | 2002-08-26 | 2007-10-31 | Takeda Pharmaceutical | Calcium receptor modulating compound and use thereof |
| NZ538223A (en) | 2002-08-26 | 2008-03-28 | Takeda Pharmaceutical | Calcium receptor modulating compound and use thereof |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US20060183746A1 (en) | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| WO2006053121A2 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| EP1831168B1 (en) | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
| ES2543607T3 (es) | 2005-03-10 | 2015-08-20 | Gilead Connecticut, Inc. | Ciertas amidas sustituidas, método de obtención, y método de su uso |
| ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
| US7786130B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| WO2007026720A1 (ja) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | 縮環ピラゾール誘導体 |
| AU2006285599A1 (en) | 2005-09-01 | 2007-03-08 | Astellas Pharma Inc. | Pyridazinone derivatives used for the treatment of pain |
| MX2008008642A (es) | 2006-01-13 | 2008-09-12 | Pharmacyclics Inc | Inhibidores de las tirosina cinasas y usos de los mismos. |
| JP5682051B2 (ja) | 2006-05-18 | 2015-03-11 | ファーマサイクリックス，インク． | 細胞内キナーゼ阻害剤 |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| PE20081370A1 (es) | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| EP2530083B1 (en) | 2006-09-22 | 2016-04-27 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2664147A1 (en) | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| EP2089391B1 (en) | 2006-11-03 | 2013-01-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| TWI552752B (zh) | 2007-10-19 | 2016-10-11 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| CN101835755B (zh) | 2007-10-23 | 2013-12-11 | 霍夫曼-拉罗奇有限公司 | 激酶抑制剂 |
| CA2708361C (en) | 2007-12-14 | 2016-06-07 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
| WO2009098144A1 (en) | 2008-02-05 | 2009-08-13 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
| AU2009244291B2 (en) | 2008-05-06 | 2014-02-13 | Genentech, Inc. | Substituted amides, method of making, and use as Btk inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| NZ589843A (en) | 2008-06-27 | 2012-12-21 | Avila Therapeutics Inc | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors |
| CA2728683C (en) | 2008-07-02 | 2017-05-02 | F.Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| WO2010006947A1 (en) | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| EP2307418B1 (en) | 2008-07-18 | 2014-03-12 | F.Hoffmann-La Roche Ag | Novel phenylimidazopyrazines |
| CN102164604A (zh) | 2008-07-24 | 2011-08-24 | 百时美施贵宝公司 | 用作激酶调节剂的稠合杂环化合物 |
| WO2010028236A1 (en) | 2008-09-05 | 2010-03-11 | Avila Therapeutics, Inc. | Algorithm for designing irreversible inhibitors |
| CA2740792C (en) | 2008-10-31 | 2016-06-21 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US8084620B2 (en) | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| CA2748181C (en) | 2009-01-06 | 2019-07-16 | Nathanael S. Gray | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2010122038A1 (en) | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| US8586751B2 (en) | 2009-06-12 | 2013-11-19 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| PT2473049T (pt) | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CN103038233B (zh) | 2010-05-07 | 2017-06-20 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
| LT2578585T (lt) | 2010-05-31 | 2016-10-10 | Ono Pharmaceutical Co., Ltd. | Purinono darinys kaip btk kinazės inhibitorius |
| NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EP2582668B1 (en) | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| CN105061438B (zh) | 2010-06-23 | 2017-07-04 | 韩美科学株式会社 | 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物 |
| US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
| DK2603081T3 (en) | 2010-08-10 | 2017-01-16 | Celgene Avilomics Res Inc | COLLECTED BY A BTK INHIBITOR |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| CN106220614B (zh) | 2010-09-01 | 2019-07-16 | 吉利德康涅狄格有限公司 | 吡啶酮/吡嗪酮、其制备方法及使用方法 |
| KR20180031823A (ko) | 2010-09-01 | 2018-03-28 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
| WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| CA2760174A1 (en) | 2011-12-01 | 2013-06-01 | Pharmascience Inc. | Protein kinase inhibitors and uses thereof |
| EP2699577A1 (en) | 2011-04-20 | 2014-02-26 | Glaxo Group Limited | Tetrahydropyrazolo [1,5 -a]pyrimidine as anti -tuberculosis compounds |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| AU2012257802A1 (en) | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
| US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| LT2718270T (lt) | 2011-06-10 | 2022-08-10 | Merck Patent Gmbh | Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| HUE031980T2 (en) * | 2013-04-25 | 2017-08-28 | Beigene Ltd | Condensed heterocyclic compounds as protein kinase inhibitors |
| CA3080200A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| TWI660739B (zh) | 2013-10-25 | 2019-06-01 | 製藥公司 | 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法 |
| US10544225B2 (en) | 2014-07-03 | 2020-01-28 | Beigene, Ltd. | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics |
| WO2016008411A1 (en) * | 2014-07-18 | 2016-01-21 | Beigene, Ltd. | 5-amino-4-carbamoyl-pyrazole compounds as selective and irreversible t790m over wt-egfr kinase inhibitors and use thereof |
| PL3179992T3 (pl) | 2014-08-11 | 2022-08-16 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1 |
| US10035802B2 (en) | 2014-08-14 | 2018-07-31 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of ibrutinib |
| WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| ES2843323T3 (es) | 2014-12-18 | 2021-07-16 | Principia Biopharma Inc | Tratamiento de pénfigo |
| LT3236943T (lt) * | 2014-12-24 | 2023-04-11 | Principia Biopharma Inc. | Kompozicija, skirta vaistų pristatymui per klubinę ir tiesiąją žarną |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
| WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| AU2017220971A1 (en) | 2016-02-19 | 2018-08-02 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof |
| CN109563099B (zh) | 2016-08-16 | 2023-02-03 | 百济神州有限公司 | 一种化合物的晶型、其制备和用途 |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| JP2019535696A (ja) | 2016-11-25 | 2019-12-12 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピリドン誘導体の医薬組成物およびその製造方法 |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| CA3057749A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| AU2019238207A1 (en) | 2018-03-21 | 2020-10-01 | Mei Pharma, Inc. | Combination therapy |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| TW202112369A (zh) | 2019-06-10 | 2021-04-01 | 英屬開曼群島商百濟神州有限公司 | 口服膠囊劑及其製備方法 |
| WO2021018018A1 (en) | 2019-07-26 | 2021-02-04 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
| EP4041304A4 (en) | 2019-09-11 | 2023-09-27 | BeiGene, Ltd. | TREATMENT OF CANCER USING A COMBINATION COMPRISING A MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE BULLETIN INHIBITOR |
| WO2021098777A1 (en) | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| US20230089557A1 (en) | 2020-02-27 | 2023-03-23 | Beigene Switzerland Gmbh | Methods of treating dlbcl using btk inhibitors and combinations thereof |
-
2017
- 2017-08-15 CN CN201780049930.8A patent/CN109563099B/zh active Active
- 2017-08-15 SG SG11201901141WA patent/SG11201901141WA/en unknown
- 2017-08-15 IL IL264784A patent/IL264784B/en unknown
- 2017-08-15 TW TW111117667A patent/TW202233628A/zh unknown
- 2017-08-15 NZ NZ751418A patent/NZ751418A/en unknown
- 2017-08-15 IL IL293319A patent/IL293319A/en unknown
- 2017-08-15 US US16/325,447 patent/US10927117B2/en active Active
- 2017-08-15 MX MX2019001900A patent/MX2019001900A/es unknown
- 2017-08-15 EA EA201990519A patent/EA201990519A1/ru unknown
- 2017-08-15 EP EP17841172.4A patent/EP3500575A4/en active Pending
- 2017-08-15 CA CA3033827A patent/CA3033827A1/en active Pending
- 2017-08-15 CN CN202310119012.5A patent/CN116478166A/zh active Pending
- 2017-08-15 AU AU2017314178A patent/AU2017314178B2/en active Active
- 2017-08-15 JP JP2019508889A patent/JP7402685B2/ja active Active
- 2017-08-15 CN CN202310094009.2A patent/CN116478165A/zh active Pending
- 2017-08-15 TW TW106127682A patent/TWI760356B/zh active
- 2017-08-15 EP EP24160079.0A patent/EP4353322A2/en active Pending
- 2017-08-15 BR BR112019003205A patent/BR112019003205A8/pt active Search and Examination
- 2017-08-15 KR KR1020237039678A patent/KR20230162137A/ko not_active Application Discontinuation
- 2017-08-15 KR KR1020197007529A patent/KR102604975B1/ko active IP Right Grant
- 2017-08-15 WO PCT/IB2017/054955 patent/WO2018033853A2/en unknown
-
2019
- 2019-02-13 ZA ZA2019/00919A patent/ZA201900919B/en unknown
-
2021
- 2021-01-12 US US17/146,855 patent/US20210130363A1/en not_active Abandoned
-
2022
- 2022-01-17 AU AU2022200278A patent/AU2022200278B2/en active Active
- 2022-03-01 JP JP2022030942A patent/JP7413419B2/ja active Active
- 2022-05-10 US US17/740,877 patent/US20220274994A1/en not_active Abandoned
- 2022-05-10 US US17/740,882 patent/US11591340B2/en active Active
- 2022-07-06 US US17/858,827 patent/US11814389B2/en active Active
- 2022-07-06 US US17/858,826 patent/US11884674B2/en active Active
- 2022-09-02 US US17/901,951 patent/US11851437B2/en active Active
-
2023
- 2023-03-07 US US18/118,555 patent/US20230242542A1/en active Pending
- 2023-11-03 US US18/386,777 patent/US20240092786A1/en active Pending
- 2023-12-01 US US18/526,535 patent/US11970500B1/en active Active
- 2023-12-27 JP JP2023220256A patent/JP2024026550A/ja active Pending
-
2024
- 2024-01-03 AU AU2024200030A patent/AU2024200030A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022071072A5 (ja) | ||
| JP2019528276A5 (ja) | ||
| JP2022121594A5 (ja) | ||
| IL258732A (en) | Salts and their benzene and polymorphs | |
| JP5453559B1 (ja) | 晶癖を有する結晶及び該結晶を加工してなる医薬組成物 | |
| JP2009506014A5 (ja) | ||
| JP2020508338A5 (ja) | ||
| US10556863B1 (en) | Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof | |
| CN102367252A (zh) | 一种盐酸托烷司琼化合物 | |
| US20210171536A1 (en) | Compound of eoc315 mod.i crystal form and preparation method thereof | |
| AU2023200013A1 (en) | Methods for making and using endoxifen | |
| JP2016505071A5 (ja) | ||
| KR20140129164A (ko) | 히스톤 데아세틸라아제 억제제 및 파조파닙의 조합물 및 이의 용도 | |
| US20180193334A1 (en) | Pharmaceutical composition of vortioxetine or salt thereof, and preparation method therefor | |
| JP2013526491A (ja) | メチソシルデナフィル・クエン酸塩結晶型ｏ及びその調製方法並びに応用 | |
| JP2009541455A5 (ja) | ||
| WO2014056396A1 (zh) | 甲磺酸氟马替尼晶型及其制备方法和用途 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| AU2016269359B2 (en) | Sodium salt of uric acid transporter inhibitor and crystalline form thereof | |
| CN102241608A (zh) | 瑞替加滨化合物及其组合物 | |
| CN102234265A (zh) | 兰索拉唑化合物 | |
| JPWO2020069024A5 (ja) | ||
| EP3378479B1 (en) | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | |
| JP2020524707A (ja) | 塩酸メフパリブの多形体およびその製造方法と使用 | |
| AU2011288091B2 (en) | Crystals of Tenofovir disoproxil fumarate |